Chart Industries, Inc. · NYSE:GTLS
Chart Industries — Natixis Bleichroeder Hidden Gems Conference 2007
23 slides from Chart Industries's conference presentation, Oct 9, 2007
Slide 1: Natixis Bleichroeder Hidden Gems Conference October 9, 2007
Natixis Bleichroeder Hidden Gems Conference October 9, 2007
Slide 2: Disclosure
Disclosure This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as "may", "might", "should", "will", "expect", "plan", "anticipate", "believe", "estimate", "project", "intend", "future", "potential"
Slide 3: Section 1: Company Overview
SECTION 1 Company Overview Sam Thomas Chairman, Chief Executive Officer and President
Slide 4: Company Overview
U.S. Europe Asia Americas (Non-U.S.) RoW % Revenue 0.48 0.22 0.16 0.06 0.1 General Industrial Energy BioMedical % Revenue 0.3 0.56 0.14 Energy industry is the largest end-user of the Company's products #1 or #2 in all primary markets served Global operations with 12 manufacturing facilities and appr
Slide 5: E&C Segment Overview
VIP for LNG and Vacuum Systems Heat Exchangers Cold Boxes % Revenue 12 67 21 Heat Exchanger Cold Box Production Heat Exchangers 67% LNG VIP and Vacuum Systems 12% Process Systems / Cold Boxes 21% LTM 6/30/07 Sales by Product Highlights Leading provider of heat exchangers and cold boxes critical to L
Slide 6: D&S Segment Overview
Bulk Storage Systems Packaged Gas Systems VIP, Systems and Components Parts Repair and Onsite Service Beverage Liquid CO2 LNG Vehicle Fuel Systems % Revenue 0.51 0.27 0.04 0.07 0.07 0.04 LTM 6/30/07 Sales by Product Highlights 40% of segment sales derived from products used in energy applications; 5
Slide 7: BioMedical Segment Overview
BioMedical Segment Overview LTM 6/30/07 Sales by Product Highlights Strong expected growth in respiratory therapy and biomedical research, led by international markets End markets include: Home healthcare and nursing home Biotechnology and biosecurity Animal breeding Respiratory Therapy Systems Biol
Slide 8: Section: Chart Investment Highlights
SECTION 2 Chart Investment Highlights Sam Thomas Chairman, Chief Executive Officer and President
Slide 9: Summary Investment Highlights
Summary Investment Highlights Strong and growing end markets Infrastructure spend of $250 billion expected over next 30 years LNG liquefaction capacity expected to grow 15% annually Well positioned in areas of strong economic growth The Market Leader Leading market position in all segments Significa
Slide 10: Positive Energy Market Fundamentals
Positive Energy Market Fundamentals Sources: "LNG World Energy Outlook" May 19-20, 2005 International Energy Agency Presentation; BP Statistical Review; Energy Information Administration Chart is well-positioned to capitalize on the strong demand for energy and the increasing use of natural gas and
Slide 11: Strong Industrial Gas Market
On-Site Gas Bulk Storage Systems Packaged Systems Market Size 26 25 49 On-Site Gas 26% On-Site Gas Bulk Storage Systems Packaged Systems Market Size 22 27 51 Strong Industrial Gas Market Industrial Gas Growth is Expected to be Robust, Significantly Exceeding GDP Growth Source: Spiritus Consulting An
Slide 12: Leading Proprietary Technology and Designs
Satellite LNG Storage Leading Proprietary Technology and Designs Extend competitive advantage in use of proprietary vacuum insulation manufacturing technology Take advantage of leading proprietary technology and designs through new product development Brazed Aluminum Heat Exchangers Microbulk Air Co
Slide 13: Global Manufacturing and Distribution Platform
Operating leverage allows substantial capacity expansion with minimal capex Global Manufacturing and Distribution Platform Manufacturing facilities are strategically located in low-cost countries and near centers of demand Corporate Energy & Chemicals Distribution & Storage BioMedical Total: Manufac
Slide 14: Strong Sales Growth Combined With...
Strong Sales Growth Combined With... BioMedical D&S E&C Total 2003 66.6 140.3 58.6 265.5 2004 73.3 162.6 69.6 305.6 2005 72.9 209.2 121.1 403.2 2006 78 268.303 190.673 537.45 LTM 6/30/07 85 305 217 607 D&S E&C ($MM) CAGR = 27% Drivers of Growth Significant exposure to global energy demand growth LNG
Slide 15: Strong Track Record of Successful Execution
Strong Track Record of Successful Execution... Experienced management has delivered strong performance since 2003 250 combined years of related experience Management team has stake in the ownership and continued success of the Company Impressive growth 27% Sales and 35% Adjusted EBITDA CAGRs since 2
Slide 16: Large Backlog Provides High Sales Visibility
Large Backlog Provides High Sales Visibility 2003 2004 2005 2006 6/30/2007 BioMed 1.8 4.6 6.4 6.415 7 D&S 28 53.8 79.5 105.07 93 E&C 19.8 70.8 147.7 207.668 315 Total 49.6 129.2 233.6 319.153 415 ($MM) D&S E&C BioMed
Slide 17: Strong Cash Flow and Rapid Delevering
10/1/2005 3/1/2006 6/1/2007 Net Debt 333.626 322.051 236 0 0 0 0 Leverage 5.098 4.107 2.3 117 124.146 281 (1) Leverage ratio defined as total debt less cash and equivalents divided by Adjusted EBITDA. Drivers of Growth ....Strong Cash Flow and Rapid Delevering Strong free cash flow generation Flexib
Slide 18: Section: Conclusion
SECTION 3 Conclusion Sam Thomas Chairman, Chief Executive Officer and President
Slide 19: Delivering on Commitments Since the IPO
At IPO Current 15 32.16 2005 2006 6/30/07 234 319 415 2005 2006 LTM 6/30/07 511 606 749 2005 2006 LTM 6/30/07 403 537 607 2005 2006 LTM 6/30/07 70 89 101 2005 2006 LTM 6/30/07 NM 0.99 1.14 Delivering on Commitments Since the IPO Financial Metrics Performance Sales ($MM) % Growth 33% 13% Adjusted EBI
Slide 20: Summary Investment Highlights
Summary Investment Highlights Strong and growing end markets Infrastructure spend of $250 billion expected over next 30 years LNG liquefaction capacity expected to grow 15% annually Well positioned in areas of strong economic growth The Market Leader Leading market position in all segments Significa
Slide 21: Appendix: Reconciliation of Net Income to Adjusted EBITDA
SECTION 4 Appendix Reconciliation of Net Income to Adjusted EBITDA
Slide 22: Reconciliation of Net Income to Adjusted EBITDA
Reconciliation of Net Income to Adjusted EBITDA In Millions Years Ended December 31, Years Ended December 31, Years Ended December 31, Years Ended December 31, Years Ended December 31, Years Ended December 31, Years Ended December 31, LTM 2003 2004 2005 2006 6/30/2007 Net income (loss) $ (7) $ 23 $
Slide 23: Chart: Innovation. Experience. Performance.
CHART 2 ® Innovation. Experience. Performance.™
Chart Industries — Natixis Bleichroeder Hidden Gems Conference 2007 on 6ix